. 2022 May 18;16(4):579–599. doi: 10.1007/s12079-022-00671-5

Table 1.

Correlations between KDM5A expression with the clinical characteristics of patients with PRAD

Characteristics		N = 60	KDM5A expression		p value
Characteristics		N = 60	Low (n = 31)	High (n = 29)	p value
Age (years)	< 65	25	14	11	0.609
	≥ 65	35	17	18	0.609
PSA (ng/mL)	≥ 20	33	14	19	0.1287
PSA (ng/mL)	< 20	27	17	10	0.1287
Bone metastasis	Positive	29	9	20	0.0041**
Bone metastasis	Negative	31	22	9	0.0041**
Gleason score	≥ 7	39	16	23	0.032*
Gleason score	< 7	21	15	6	0.032*
Lymph-node metastasis	Positive	32	12	20	0.023*
Lymph-node metastasis	Negative	28	19	9	0.023*
Tumor stage	T2	24	17	7	0.0193*
Tumor stage	T3 + T4	36	14	22	0.0193*

Clinical characteristics of patients were analyzed using the Fisher's exact test; *p < 0.05; ** p < 0.01; KDM5A lysine demethylase 5A, PRAD prostate adenocarcinoma, PSA prostate-specific antigen